Vertex Pharmaceuticals Inc. (VRTX)
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $414.86, representing a -1.49% change from its previous close.
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $403.3, indicating a -1.36% shift from the previous trading day.
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $408.85, representing a +1.15% change from its previous close.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $387.15, denoting a -1.08% move from the preceding trading day.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Pharmaceuticals Incorporated (VRTX) Q2 2025 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Charles F. Wagner - Executive VP, COO & CFO Duncan McKechnie - Corporate Participant Reshma Kewalramani - CEO, President & Director Susie Lisa - Senior Vice President of Investor Relations Conference Call Participants David Reed Risinger - Leerink Partners LLC, Research Division Divya Rao - TD Cowen, Research Division Eliana Rachel Merle - UBS Investment Bank, Research Division Evan David Seigerman - BMO Capital Markets Equity Research Geoffrey Christopher Meacham - Citigroup Inc., Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Terence C.
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.52 per share, beating the Zacks Consensus Estimate of $4.24 per share. This compares to a loss of $12.83 per share a year ago.
How Will VRTX Stock React To Its Upcoming Earnings?
Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, August 4, 2025. Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings announcements.
